The unexpected PD-L1 suppression function of celery-derived extracellular vesicles improves lung cancer chemotherapy efficacy DOI Open Access
Xin Lü, Zhuang Yu, Junjun Wang

et al.

Extracellular Vesicles and Circulating Nucleic Acids, Journal Year: 2024, Volume and Issue: 5(4), P. 697 - 713

Published: Nov. 9, 2024

Aim: The article explores celery-derived extracellular vesicles (CDEVs), characterized by high cellular uptake, low immunogenicity, and stability, as a therapeutic strategy for antitumor nanomedicines. Methods: methods employed in this study include vitro cell experiments such co-culture, Western Blot, flow cytometry. In vivo were conducted C57BL/6 tumor-bearing mice subcutaneously injected with Lewis lung carcinoma (LLC) cells. encompassed parameters survival rate, body weight, tumor size, cytometry, immunohistochemistry, spectral live imaging system. Results: Our revealed that CDEVs could be used drugs to effectively downregulate the phosphorylated signal transducer activator of transcription 3 (p-STAT3)/programmed death ligand 1 (PD-L1) axis cancer co-culture experiments, observed impede expression PD-L1, thereby interfering interaction between PD-L1 programmed (PD-1) subsequently preventing suppression T distribution loaded paclitaxel (PTX) demonstrated better targeting capabilities. Remarkably, following CDEVs-PTX treatment, CD8+ levels increased, presumably leading improved effects. Conclusion: not only serve drug carriers but also function themselves; such, through single administration CDEVs, it is possible combine immunotherapy chemotherapy achieve effects two, providing more comprehensive effective treatment promises improve outcomes reduce adverse therapy.

Language: Английский

Lipidic and Inorganic Nanoparticles for Targeted Glioblastoma Multiforme Therapy: Advances and Strategies DOI Creative Commons
Ewelina Musielak, Violetta Krajka‐Kuźniak

Micro, Journal Year: 2025, Volume and Issue: 5(1), P. 2 - 2

Published: Jan. 3, 2025

Due to their biocompatibility, nontoxicity, and surface conjugation properties, nanomaterials are effective nanocarriers capable of encapsulating chemotherapeutic drugs facilitating targeted delivery across the blood–brain barrier (BBB). Although research on nanoparticles for brain cancer treatment is still in its early stages, these systems hold great potential revolutionize drug delivery. Glioblastoma multiforme (GBM) one most common lethal tumors, heterogeneous aggressive nature complicates current treatments, which primarily rely surgery. One significant obstacles poor penetration BBB. Moreover, GBM often referred as a “cold” tumor, characterized by an immunosuppressive tumor microenvironment (TME) minimal immune cell infiltration, limits effectiveness immunotherapies. Therefore, developing novel, more treatments critical improving survival rate patients. Current strategies enhancing outcomes focus controlled, agents cells BBB using nanoparticles. These therapies must be designed engage specialized transport systems, allowing efficient penetration, improved therapeutic efficacy, reduced systemic toxicity degradation. Lipid inorganic can enhance while minimizing side effects. formulations may include epitopes—small antigen fragments that bind directly free antibodies, B receptors, or T receptors—that interact with enable crossing, thereby boosting efficacy. Lipid-based (LNPs), such liposomes, niosomes, solid lipid (SLNs), nanostructured carriers (NLCs), among promising due unique including size, modification capabilities, proven biosafety. Additionally, gold nanoparticles, mesoporous silica, superparamagnetic iron oxide dendrimers offer alternatives. Inorganic (INPs) easily engineered, surfaces modified various elements biological ligands delivery, biocompatibility. Strategies engineering functionalization have been employed ensure biocompatibility reduce cytotoxicity, making safer clinical applications. The use INPs has shown promise efficacy traditional like chemotherapy, radiotherapy, gene therapy, well advancing newer strategies, immunotherapy, photothermal photodynamic therapies, magnetic hyperthermia. This article reviews latest treating GBM, focusing active passive targeting approaches.

Language: Английский

Citations

3
Nanomaterials in cancer immunotherapy: targeting cancer-associated fibroblasts DOI Creative Commons

Zhongsong Zhang,

Long Chen

Cancer Nanotechnology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 17, 2025

Emphasizing the significance of cancer-associated fibroblasts (CAFs), non-malignant yet pivotal players within tumor microenvironment (TME), this review illuminates role inflammatory subtype (iCAF) as catalysts in cancer proliferation, metastasis, and therapeutic resistance. Given their paramount importance, targeting CAFs emerges a robust strategy evolving landscape immunotherapy. Nanomaterials, distinguished by unique features malleability, hold considerable promise biomedicine, especially precision-oriented domain therapy. Their aptitude for modulating immune responses, amplifying drug efficacy through precise delivery, discerningly focusing on cells TME situates nanomaterials formidable tools to transcend boundaries set conventional treatments. This scrutinizes convoluted interplay among CAFs, cells, TME. It further showcases widely utilized management. We underscore potential nanoscale delivery systems directed at underscoring transformative power revolutionizing therapies, enhancing precision, culminating improved patient outcomes.

Language: Английский

Citations

2
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies DOI Creative Commons

Kexin Ai,

Bowen Liu, Xiaomei Chen

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: Nov. 5, 2024

Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various hematological malignancies. However, its application solid tumors is still limited. Clinical studies report suboptimal outcomes such as reduced cytotoxicity of CAR-T cells and tumor evasion, underscoring the need to address challenges sliding cells. Despite improvements from fourth next-generation cells, new include systemic toxicity continuously secreted proteins, low productivity, elevated costs. Recent research targets genetic modifications boost killing potential, metabolic interventions hinder progression, diverse combination strategies enhance therapy. Efforts reduce duration cost developing allogenic in-vivo approaches, promising significant future advancements. Concurrently, innovative technologies platforms potential overcome limitations treating tumors. This review explores optimize therapies for tumors, focusing on enhancing overcoming restrictions. We summarize recent advances T subset selection, structural modifications, infiltration enhancement, interventions, production optimization, integration novel technologies, presenting therapeutic approaches that could improve therapy's applicability

Language: Английский

Citations

7
Design of nanosystems for melanoma treatment DOI Creative Commons
Asal Farasatkia, Lidia Maeso,

Hamidreza Gharibi

et al.

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown, P. 124701 - 124701

Published: Sept. 1, 2024

Language: Английский

Citations

4
Nanoparticles, a promising treatment for gastric cancer DOI Creative Commons
Hua Dong, Xiexing Wu,

Zebin Wu

et al.

Smart Materials in Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Targeting tumor microenvironment with RGD-functionalized nanoparticles for precision cancer therapy DOI Creative Commons
Sara Lorenzoni, Carlos Rodríguez‐Nogales, Marı́a J. Blanco-Prı́eto

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217536 - 217536

Published: Feb. 1, 2025

Language: Английский

Citations

0
Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy DOI Creative Commons

Yuli Ge,

Qiong Zhou, Fan Pan

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2371 - 2394

Published: Feb. 1, 2025

Lung cancer is the leading cause of cancer-related mortality globally, with non-small cell lung (NSCLC) constituting 85% cases. Immune checkpoint inhibitors (ICIs) represented by anti-programmed death protein 1 (PD-1)/ programmed ligand (PD-L1) have emerged as a promising frontier in treatment, effectively extending survival patients NSCLC. However, efficacy ICIs exhibits significant variability across diverse patient populations, substantial proportion showing poor responsiveness and acquired resistance those initially responsive to treatments. With advancement nanotechnology, nanoparticles offer unique advantages tumor immunotherapy, including high permeability prolonged retention(EPR) effects, enhanced drug delivery stability, modulation inflammatory microenvironment(TME). This review summarizes mechanisms NSCLC, focusing on antigens loss defective antigen processing presentation, failure T priming, impaired migration infiltration, immunosuppressive TME, genetic mutations. Furthermore, we discuss how nanoparticles, through their intrinsic properties such EPR effect, active targeting shielding self-regulatory synergistic can potentiate reverse resistance. In conclusion, serve robust platform for ICIs-based NSCLC therapy, aiding overcoming challenges.

Language: Английский

Citations

0
Nanomaterials for targeted drug delivery for immunotherapy of digestive tract tumors DOI Creative Commons
Mingzhu Li,

Ningxin Li,

Haozhe Piao

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 5, 2025

The incidence and mortality rates of digestive tract tumors, especially gastric colorectal cancers, are high worldwide. Owing to their unique advantages, such as efficient drug loading, safety, targeting properties, nanoparticles (NPs) have demonstrated great potential in the treatment gastrointestinal tumors. However, practical application is limited by several factors, costs, few clinical trials, long approval periods. In this review, we summarize three types immunotherapeutic nanomaterial drugs for tumors: organic, inorganic, hybrid nanomaterials. This article also discusses current status research development field advantages each type material provide theoretical references developing new advancing research.

Language: Английский

Citations

0
Advancements in Nanotechnology for Targeted and Controlled Drug Delivery in Hematologic Malignancies: Shaping the Future of Targeted Therapeutics DOI Creative Commons
Abdurraouf Mokhtar Mahmoud,

Clara Deambrogi

Applied Biosciences, Journal Year: 2025, Volume and Issue: 4(1), P. 16 - 16

Published: March 5, 2025

Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, pose significant therapeutic challenges due to their heterogeneity high relapse rates. Nanotechnology has emerged as a promising avenue for precision drug delivery in these allowing enhanced concentration at tumor sites reducing systemic toxicity. Recent developments nanocarriers—such liposomes, polymeric nanoparticles, inorganic nanoparticles—have enabled targeted approaches, utilizing molecular markers specific malignant cells increase efficacy while minimizing adverse effects. Evidence from preclinical clinical studies underscores the potential of nanotechnology improve patient outcomes by facilitating controlled release, improved bioavailability, reduced However, translating advancements into practice requires further research validate safety efficacy. This review provides comprehensive analysis latest innovations hematologic addressing current achievements future directions integrating approaches Clinical Hemato-Oncology.

Language: Английский

Citations

0
Bifunctional chemokine-nanobody fusion protein enhances neutrophil recruitment to impede Acanthamoeba immune evasion DOI
Zhenyu Wei,

Jianlong Yuan,

Q Chen

et al.

EBioMedicine, Journal Year: 2025, Volume and Issue: 115, P. 105685 - 105685

Published: April 12, 2025

Language: Английский

Citations

0